CWBR Stock Overview
A clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CohBar, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.000001 |
| Beta | 1.38 |
| 11 Month Change | -2.00% |
| 3 Month Change | 13.95% |
| 1 Year Change | -30.10% |
| 33 Year Change | -96.49% |
| 5 Year Change | -99.00% |
| Change since IPO | -98.83% |
Recent News & Updates
Recent updates
CohBar stock gains on 1-for-30 reverse stock split
Sep 22Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation
Jun 13
CohBar appoints Joseph Sarret as CEO and Director
Apr 27CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS
Jan 11CohBar EPS in-line
Nov 16CohBar (CWBR) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| CWBR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | 4.0% | 2.0% |
| 1Y | -30.1% | 18.0% | 32.4% |
Return vs Industry: CWBR underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: CWBR underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CWBR volatility | |
|---|---|
| CWBR Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CWBR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CWBR's weekly volatility has decreased from 8451526% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 10 | n/a | www.cohbar.com |
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
CohBar, Inc. Fundamentals Summary
| CWBR fundamental statistics | |
|---|---|
| Market cap | US$1.49m |
| Earnings (TTM) | -US$12.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs CWBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CWBR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.69m |
| Earnings | -US$12.69m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CWBR perform over the long term?
See historical performance and comparison